Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer (NCT05761951)

🧪 Interventions in This Study

• DKN-01 (DRUG)
• Pembrolizumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• M D Anderson Cancer Center — Houston, Texas

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Endometrial Cancer

• Selective Surgical Staging for the Treatment of Endometrial Cancer Based on Intraoperative Consultation — Lexington, Kentucky
• Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) — Mobile, Alabama
• A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer — Little Rock, Arkansas
• Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line — Garran,
• Activity and Cancer Survivorship Exercise Pilot — Iowa City, Iowa

Explore by condition: All Endometrial Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.